KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.45

Health-related quality of life outcomes associated with zanubrutinib versus ibrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: results from the ALPINE Trial.

Constantine S Tam, Nicole Lamanna, Susan M O'Brien, Lugui Qiu, Keri Yang, Gisoo Barnes, Ken Wu, Tommi Salmi, Jennifer R Brown

Curr Med Res Opin 39(11) 1497-1503

PMID37752892
PMCID-
DOI10.1080/03007995.2023.2262378
发表日期2023-09-27
入排依据:The study is a secondary analysis of a Phase III randomized controlled trial comparing zanubrutinib to ibrutinib in R/R CLL/SLL, with drug intervention and human oncology context. However, it is excluded because the primary endpoint is health-related quality of life (a patient-reported outcome), not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The report is classified as secondary, not primary.
摘要

摘要

OBJECTIVE: The purpose of this analysis was to assess health-related quality of life (HRQoL) in patients treated with zanubrutinib and ibrutinib in the ALPINE trial (NCT03734016). METHODS: HRQoL was measured by the EORTC QLQ-C30 and EQ-5D-5L at baseline, cycle 1, and every third cycle until the end of treatment. Key patient-reported outcome (PRO) endpoints included global health status (GHS), physical and role functioning, as well as symptoms of fatigue, pain, diarrhea, and nausea/vomiting. A mixed model repeated-measure analysis using key PRO endpoints at key clinical cycles (cycles 7 and 13) was performed. RESULTS: 652 patients were randomized to receive zanubrutinib (n = 327) or ibrutinib (n = 325). By cycle 7, GHS scores improved with zanubrutinib versus ibrutinib, and in cycle 13, GHS scores remained higher in the zanubrutinib arm. The zanubrutinib arm experienced clinically meaningful improvements in physical and role functioning, as well as pain and fatigue symptoms at both cycles. Patients in the zanubrutinib arm reported lower diarrhea scores. Nausea/vomiting scores maintained in both arms. EQ-VAS scores showed greater improvement from baseline at both cycle 7 (7.92 versus 3.44) and cycle 13 (7.75 versus 3.92) of treatment with zanubrutinib compared to ibrutinib, respectively. CONCLUSIONS: Patients with R/R CLL/SLL treated with zanubrutinib demonstrated improvement versus ibrutinib in the GHS scale at cycle 7. Other endpoints continued to improve, suggesting treatment with zanubrutinib positively affected HRQoL over time. Given the generally good HRQoL at baseline in both arms, the differences between the arms were not significant.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。